FIELD OF THE INVENTION
The present invention relates to the crystalline Forms A, B, C and D of fevipiprant and pharmaceutical composition thereof. The present invention further provide the processes for the preparation of the crystalline Forms A, B, C and D of fevipiprant.
The present invention further provides amorphous solid dispersion of fevipiprant of Formula I with pharmaceutical acceptable excipients and process of preparation thereof.
Formula I
BACKGROUND OF THE INVENTION
The compound, 2-[2-methyl-1 -[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo [2,3-b]pyridine-3-yl]acetic acid is CRTh2 receptor antagonist for the treatment of an obstructive or inflammatory airway of disease such as asthma and atopic dermatitis. It is also known as Fevipiprant and is represented by structure of Formula I:

Formula I
Fevipiprant, the compound of Formula I is disclosed in US patent 7,666,878 which also refers to its method of synthesis. US'878 further discloses a method of crystallization of fevipiprant in IP A/water (1:3).
PCT application 2017/056001 Al discloses purification of fevipiprant by using seeding techniques. The crystals of fevipiprant is added to methyl isobutyl ketone (MIBK) layer containing crude fevipiprant, along with heptane. The suspension so obtained is filtered and the filter cake is washed with pre-cooled HPTF (heptane fraction) and MIBK, then with acetone/water and finally with water.
The alternate method for crystallization of fevipiprant as disclosed in WO'001 involves seeding methyl isobutyl ketone (MIBK) layer containing crude fevipiprant. The crystals so obtained are filtered and washed with MIBK:-water
(1:1).
i.
Although there are certain known prior published applications that discloses the purification/ crystallization processes of fevipiprant, however the known methods are not only lengthy but also tedious to be performed at commercial scale. The present invention is focussed towards the preparation of new crystalline forms of fevipiprant that can be easily formulated. Further, present invention provides a process for purification/ crystallization of fevipiprant with economically friendly

solvents and less tedious reaction conditions that can produce stable crystalline form of fevipiprant that are reproducible at large scale production.
OBJECT OF THE INVENTION
The main object of the present invention is to develop novel crystalline forms of fevipiprant.
Another object of the present invention is to provide novel crystalline Forms A, B, C, and D of fevipiprant which possesses good stability, good processability and other favourable properties.
Another object.of the present invention is to provide a process for preparing novel crystalline Forms A, B, C, and D of fevipiprant and a composition comprising said crystalline forms along with atleast one pharmaceutical acceptable excipients.
SUMMARY OF THE INVENTION
The main aspect of the present invention relates to a crystalline Form A of fevipiprant having characteristic X-Ray Powder Diffraction. (X.RPD) peaks (29 values) at 10.55, 12.10, 17.51, 21.16 and 24.38±O.2°0.
In another aspect, the present invention provides a crystalline Form B of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) peaks (20 values) at 12.05, 13.60, 15.7 and 21;13±0.2°9.
In one another aspect, the present invention provides a crystalline Form C of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) peaks (29 values) at 4.97, 9.55, 13.79 and 21.69±O.2°0.
In one another aspect, the present invention provides a crystalline Form D of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) peaks (29 values) at 10.52, 12.55, 19.56, and 28.31±O.2°0.

In further aspect, the present invention provides a process for the preparation of a crystalline form of fevipiprant comprising the steps of:
a) adding fevipiprant to an organic solvent at 40-100°C to get a hot solution;
b) adding the hot solution to another solvent and cooling to 0-30°C; and
c) filtering and drying to get crystalline form of fevipiprant.
DETAILED DESCRIPTION
Details of the drawings:
Fig. 1 depicts X-Ray Powder Diffraction (XRPD) of crystalline Form A of
fevipiprant
Fig. 2 depicts X-Ray Powder Diffraction (XRPD) of crystalline Form B of
fevipiprant
Fig. 3 depicts X-Ray Powder Diffraction (XRPD) of crystalline Form C of
fevipirant
Fig. 4 depicts X-Ray Powder Diffraction (XRPD) of crystalline Form D of
fevipiprant
Fig. 5 depicts DSC (Differential Scanning Calorimetry) peaks of crystalline Form
A of fevipiprant
Fig. 6 depicts DSC (Differential Scanning Calorimetry) peaks of crystalline Form
B of fevipiprant
Fig. 7 depicts DSC (Differential Scanning Calorimetry) peaks of crystalline Form
C of fevipiprant
Fig. 8 depicts DSC (Differential Scanning Calorimetry) peaks of crystalline Form
D of fevipiprant
The present invention is focussed towards the development of new crystalline forms of fevipiprant by employing simple, low cost and less time consuming process wherein the crystalline forms so obtained possesses favourable properties such as good stability, and can be easily formulated.

Accordingly, in an embodiment, the present invention provides a process for the preparation of crystalline form of fevipiprant comprising the steps of:
a) adding fevipiprant in an organic solvent at 40-10.0°C to get a hot solution; . b) adding the hot solution to another solvent and cooling to 0-3 0°C; and
c) filtering and drying to get crystalline form of fevipiprant.
In a preferred embodiment, the fevipiprant used in step a) is either a crude mass, or an amorphous form or any of the crystalline forms wherein said fevipiprant is prepared by any conventional or prior known methods.
i In another embodiment, the organic solvent used to dissolve fevipiprant in step a)
is selected from, but not limited to, the group comprising of ketones such as methyl
isobutyl ketone, methyl tert-butyl ketone, acetone and the like; alcohol such as
ethanol, methanol, n-propanol, butanol, isobutanol and tert-butanol; acetates such
as ethyl acetate, propyl acetate, ri-pentyl acetate, isopropyl acetate, butyl acetate
and the like; ethers such as 1,4-dioxane, tetrahydrofuran, methyl tetrahydrofuran;
and mixture thereof, and preferably the organic solvent is selected from methyl
isobutyl ketone, methanol, ethyl acetate, 1,4-dioxane, and mixture thereof
In another embodiment, the "another solvent" to which the hot solution is added in step b) is selected from the group comprising of organic and inorganic solvents such as n-heptane, cyclohexane, n-hexane, water, and mixture thereof.
In another embodiment, the present invention provides a crystalline form of fevipiprant selected from crystalline Form A, B, C and D wherein,
a) crystalline Form A is characterized by XRD pattern having 20 value of 10.55, 12.10, 17.51, 21.16 and 24.38±O.2°0;
b) crystalline Form B is characterized by XRD pattern having 20 value of 12.05, 13.60, 15.70 and 21.13±O.2°0;
c) crystalline Form C; is characterized by XRD pattern having 20 value of 4.97, 9.55, 13.79 and 21.69±O.2°0; and

d) crystalline Form D is characterized by XRD pattern having 29 value of 10.52, 12.55, 19.56, and 28.31±O.2°0.
In specific embodiment, the present invention provides a crystalline form of fevipiprant selected from crystalline Form A, B, C and D wherein,
a) crystalline Form A is characterized by XRD pattern having 29 value of 10.55, 12.10, 17.51, 21.16 and 24.38±0.2°9, and by Differential Scanning Calorimetry with peak at about 210.26°C;
b) crystalline Form B is characterized by XRD pattern having 29 value of 12.05, 13.60, 15.70 and 21.13±Q.2°9, and by Differential Scanning Calorimetry with peak at about 212.61°C;
c) crystalline Form C is characterized by XRD pattern having 20 value of 4.97, 9.55, 13.79 and 21.69±0.2°9, and by Differential Scanning Calorimetry with peak atabout211.37°C;and
d) crystalline Form D is characterized by XRD pattern having 29 value of 10.52, 12.55,19.56, and 28.31±0.2°9, and by Differential Scanning Calorimetry with peak atabout210.32°C.
In a preferred embodiment, the present invention provides a crystalline Form A of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks at 10.55, 12.10, 17.51, 21.16 and 24.38±0.2°9.
In another embodiment, the present invention provides a crystalline Form A of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks at 10.55, i2.10, 14.34, 15.78, 15.99, 17.51, 17.97, 18.20, 18.41, 19.87, 20.72, 21.16, 21,36, 22.09, 22.56, 23.63, 24.06, 24.38, 25.52, 25.79, 26.12, 26.71, 26.90, 27.24, 27.45, 28.05, 28.32, 29.20, 29.55, 30.62, 31.15, 31.53, 3L89, 32.30, 32.94, 33.22, 35.41, 35.85, 36.95, 37.46, 37.82, 38.16, 38.19, 38.64, and 38.85±0.2o97 "

In another embodiment, the present' invention provides a crystalline Form A of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) as represented in Fig. 1.
In another embodiment, the present invention provides a crystalline Form A of fevipiprant having characteristic DSC ^Differential Scanning Calorimetry) with onset peak at about 208.33°C and peak at about 210.26°C.
In another embodiment, the present invention provides a crystalline Form A of fevipiprant having characteristic DSC (Differential Scanning Calorimetry) as represented in Fig. 5.
In another embodiment, the present invention provides a process for the preparation of crystalline Form A of fevipiprant, comprising the steps of:
a) adding fevipiprant in methyl isobutyl ketone at 65-90°C to get a hot solution;
b) adding the hot solution to n-heptane and cooling to 20-30°C; and
c) filtering and drying to get crystalline Form A of fevipiprant.
In another preferred embodiment, the present invention provides a crystalline Form B of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks at 12.05, 13.60, 15.70 and 21.13±0.2°9.
In another embodiment, the present invention present invention provides a crystalline Form B of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks 4.94, 8.58, 8.87, 9.04,9.32, 10.51, 12.05, 12.68, 13.09, 13.60, 14.28, 14.85, 15.70, 16.07, 17.46., 17,91, 18.19, 18.44, 19.84, 20.20, 20.68, 21.13, 21.70, 22.03, 22.56, 22.87, 23.57, 23.97, 24.34, 24.70, 25.47, 26.12, 26.60, 26779, 27.18, 27.43, 28.02, 28.31, 28.61, 29.58, 30.02, 30.25, 30.45, 31.09, 31.48, 31.88, 32.27, 32.90, 33.14, and 33.65±O.2°0.

In another embodiment, the present invention present invention provides a crystalline Form B of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) as represented in Fig. 2.
In another embodiment, the present invention provides a crystalline Form B of fevipiprant having characteristic DSC (Differential Scanning Calorimetry) with onset peak at about 210.45°C and peak at about 212.61°C.
In another embodiment, the present invention provides a crystalline Form B of fevipiprant having characteristic DSC (Differential Scanning Calorimetry) as represented in Fig. 6.
In another embodiment, the present invention provides a process for the preparation of crystalline Form B of fevipiprant, comprising the steps of:
a) adding fevipiprant in ethyl acetate at-50-60°C to get a hot solution;
b) adding the hot solution to n-heptane and cooling to 20-3 0°C; and
c) filtering and drying to get crystalline Form B of fevipiprant.
In one another preferred embodiment, the present invention provides a crystalline Form C of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks at 4.97, 9.55, 13.79 and 21.69±O.2°0.
In another embodiment, the present invention present invention provides a crystalline Form C of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks at 4.97, 8.60, 9.55, 9.91, 10.77, 12.85, 13.13, 13.79, .14.89, -16.26, 17.70, 17.93, 19.14, 19.72, 20.34, 21.03, 21.69, 22.11, 22.81, 23.25, 23.75, 24.34, 24.78, 25.86, 26.34, 26.76, 27.68, 28.14, 28.67, 29.08, 29.48, 29,93, 30.40,. 31.00, 31.98, 32.87, 33.99, 34.32, 35.26, 35.52, 36.29, 36.52, 37.01, 37:59, 38.35, and 39.33±0.2°9.

In another embodiment, the present invention present invention provides a crystalline Form C of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) as represented in Fig. 3.
In further embodiment, the present invention provides a crystalline Form C of feyipiprant characterized by Differential Scanning Calorimetric peak at 211.37°C with the onset at 209.58°C.
In another embodiment, the present invention present invention provides a crystalline Form C of fevipiprant characterized by Differential Scanning Calorimetric as represented in Fig. 7.
In another embodiment, the present invention provides a process for the preparation of crystalline Form C of fevipiprant, comprising the steps of:
a) adding fevipiprant in methanol at 50-60°C to get a hot solution;
b) adding water to the hot solution and cooling to 20-30°C; and
c) filtering and drying to get crystalline Form C of feyipiprant.
In one another preferred embodiment, the present invention provides a crystalline Form D of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks at 10.52, 12.55,19.56, and 28.31±0.2°9.
In one another embodiment, the present invention present invention provides a crystalline Form D of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) with peaks at 4.94, 8.56, 9.87, 10.52, 12.09, 12.55, 13.13, 13.60, 14.32, 14.88, 15.78, 16.01, 16,51, 16.62, 17,49, 17.94, 18.21, 18.43, 19.56, 19.89, 20.22, 20.68, 21.17, 21.70, 22.10, 22.82, 23.63, 24.06, 24.39, 24.74, 26.11, 26.79, 27.40, 28.04, 28.31, 29.61, 30.10, 31.63, 31.91, 32.33, 32.82, 35.87, 36.94,37.49, 38.18, and 38.59±0.2°e.

In another embodiment, the present invention provides a crystalline Form D of fevipiprant having characteristic X-Ray Powder Diffraction (XRPD) as represented in Fig. 4.
In further embodiment, the present invention provides a crystalline Form D of fevipiprant characterized by Differential Scanning Calorimetric peak at 210.32°C with the onset at 208.20°C.
In another embodiment, the present invention present invention provides a crystalline Form D of fevipiprant characterized by Differential Scanning Calorimetric as represented in Fig. 8.
In another embodiment, the present invention provides a process for the preparation of crystalline Form D of fevipiprant, comprising the steps of:
a) adding fevipiprant in 1,4-dioxane at 55-65°C to get a hot solution;
b) adding the hot solution to n-heptane and cooling to 20-30°C; and
c) filtering and drying to get crystalline Form D of fevipiprant.
In another embodiment, the present invention further relates to a composition comprising crystalline form selected from A, B, C and D of fevipiprant along with at least one pharmaceutically acceptable excipients thereof.
In another embodiment, the present application provides stable crystalline forms of fevipiprant selected from Form A, B, C and D which are suitable for formulating stable composition. In an embodiment, the present application provides stable crystalline forms of fevipiprant with less than 10% of amorphous form, preferably with less than 5% of amorphous form.and more preferably with less than 1% amorphous form and more preferably with less than 0.5% amorphous form as per X-ray diffraction analysis.

In further embodiment, crystalline forms of fevipiprant described herein are anhydrous, solvated or partially solvated or desolvated.
In another embodiment, present invention provide use of crystalline Forms A, B, C and D of fevipiprant for the treatment of an obstructive or inflammatory airway of disease such as asthma and atopic dermatitis.
In other embodiment, the crystalline forms of fevipiprant as prepared by the process of the present invention is isolated with purity of 98% or above and preferably, 99% or above.
In another embodiment, the present invention provides the crystalline forms of fevipiprant that is characterized by particle size distribution wherein, dgo is 0.1 urn to200|am.
In another embodiment, the present invention provides the crystalline forms of
fevipiprant that is characterized by particle size distribution wherein, dw is 2.0 \xm
to 150|im. '
In one more embodiment, the present invention provides a non-crystalline form or amorphous form of fevipiprant or its pharmaceutical acceptable salts, solvates, .hydrates or solid dispersions thereof.
In one another embodiment, the present invention provides a process for the
preparation of an amorphous solid dispersion of fevipiprant, comprising the steps
■of:-'
_a)-providing-a-solution-of-fevipiprant4n-a-suitable-solvent^ :
b) adding atleast one pharmaceutical^ acceptable excipient to the solution obtained in step a); and
c) isolating the amorphous solid dispersion of fevipiprant.

In further embodiment, the fevipiprant described herein, for the preparation various , amorphous solid dispersion are amorphous, or crystalline in nature. Even the reaction mixture containing fevipiprant can be used for preparing solid dispersions.
In another embodiment, the isolation in step c) above may be done using techniques such as direct filtration or by scraping, or by shaking the container, removal of the solvent include using a rotational distillation device such as a buchi rotavapor, spray drying, agitated thin film drying, freeze drying (lyophilization), and the like, or other techniques specific to the equipment used.
In further embodiment, pharmaceutically acceptable excipient may include, but not limited to an inorganic oxide such as silicon dioxide, titanium dioxide, zinc oxide, zinc dioxide, aluminium dioxide and zeolite; and organic polymers such as polyvinyl pyrrolidinone, cross linked cellulose acetate phthalate, microcrystalline cellulose, polyethylene/polyvinyl alcohol copolymer, polyethyle/polyvinyl pyrrolidinone copolymer, cross-linked carboxymethyl cellulose, povidone, povidone K-30, povidone K-60, Povidone K-90, polyvinyl pyrrolidone vinyl acetate, polyvinyl alcohol, polysorbate 80, polyethylene glycol, methyl cellulose, Eudragit S-100, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, gelucire 44/14, ethyl cellulose, D-alphatpcopheryl polyethylene glycol 1000 succinate, cellulose acetate phthalate, carboxymethylethylcellulose, cellulose derivatives; polyethylene glycol, cyclodextrins, gelatins, hypromellose phthalates, sugars, polyhydric alcohols, mannitol, lactose, fructose, sorbitol, xylitol, maltodextrin, dgxtrates, dextrins, lactitol and the like.
In a preferred embodiment, the pharmaceutically acceptable excipient includes hydroxypropyl cellulose, povidone K-30, Eudragit S-100, polyvinyl alcohol, ethyl cellulose/hydroxymethyl propyl cellulose, hydroxymethyl propyl cellulose and the like.

In another embodiment, the suitable solvent used for preparing solid dispersion may be selected from the group consisting of alcohol such as methanol, ethanol, 2-propanol, 1- butanol, 2-butanol, 1-pentanol, 2-pentanol, 3-pentanol; ketone solvents such as acetone, methyl ethyl ketone, methyl isobutyl ketone; esters solvents such as methyl acetate, ethyl acetate, isopropyl acetate; water and mixtures thereof.
The present invention is explained below by way of examples. However, the examples are provided as one of the possible way to practice the invention and should hot be considered as limitation of the scope of the invention.
EXAMPLES
REFERENCE EXAMPLE: Crystallization of Fevipiprant
Charged fevipiprant 500.0 mg in 6.0 ml of Isopropyl alcohol. Heated the reaction mass at 80°C to get clear solution. Added drop wise 4.0 ml of D.M water. Cooled down the reaction mass at 10-15°C and filtered it. Dried the material under vacuum at 50°C for l.Ohr to get crystalline fevipiprant.
EXAMPLE 1: Preparation of crystalline Form A of Fevipiprant
Charged fevipiprant 500.0 mg in 5.0ml of methyl isobutyl ketone. Heated the reaction mass at 80°C to get a clear solution. Added the solution in 50.0ml RBF containing 10.0 ml of n-Heptane and cooled down the reaction mass to 22-25°C. Filtered the solids so obtained and dried under vacuum at 50°C for l.Ohr to get crystalline Form A of fevipiprant.
EXAMPLE 2: Preparation of crystalline Form B of Fevipiprant
Charged fevipiprant 500.0 mg in 12.0 ml of ethyl acetate. Heated the reaction mass at 55-60°C to get a clear solution. Added the solution in 50.0ml RBF containing 10.0 ml of n-Heptane and cooled down the reaction mass to 22-25°C. Filtered the solids so obtained and dried under vacuum at 50°C for 1 .Ohr to get crystalline Form B of fevipiprant.

EXAMPLE 3: Preparation of crystalline Form C of Fevipiprant
Charged fevipiprant 500.0 mg in 5.0 ml of methanol. Heated the reaction mass at 50-55°C to get a clear solution. Added drop wise 5.0 ml of D.M water till precipitation. Cooled down the reaction mass to 22-25°C and filtered the crystals so obtained. Dried the crystals under vacuum at 50°C for 1 .Ohr to get crystalline Form C of fevipiprant.
EXAMPLE 4: Preparation of crystalline Form D of Fevipiprant
Charged fevipiprant 500.0mg.in 10.0 ml of 1,4-Dioxane. Heated the reaction mass at 60°C to get a clear solution. Added the solution in 50.0ml RBF containing 10.0 ml of n-Heptane. Cooled down the reaction mass to 22-25°C and filtered the crystals so obtained. Dried the crystals under vacuum at 50°C for l.Ohr to get crystalline Form D of fevipiprant.
EXAMPLE 5: Preparation of amorphous solid dispersion of Fevipiprant with hydroxypropyl cellulose
Fevipiprant (500 mg), hydroxypropyl cellulose (500 mg) and methanol (50 ml) were charged into a round bottom flask/at 25°C. The reaction mass was stirred for 15 minutes at 50°C. The reaction mass temperature cooled to 25°C. The reaction mass was filtered to remove any insoluble particles. The reaction mass was evaporated under vacuum at 50°C for over 60 minutes.
EXAMPLE 6: Preparation of amorphous solid dispersion of Fevipiprant with povidone K 30
Fevipiprant (500 mg), povidone K 30 (500 mg) and methanol (50 ml) were charged into a round bottom flask at 25°C. The reaction mass was stirred for 15 miniates at 50°C. The reaction mass temperature cooled to 25°C. The reaction mass was filtered to remove any insoluble particles. The reaction mass was evaporated under vacuum at 55°C for over 20 minutes.

EXAMPLE 7: Preparation of amorphous solid dispersion of Fevipiprant with Eudragit S-100
Fevipiprant (500'ing), Eudragit S-100 (500 mg), acetone (50 ml) and water (5 ml) weVe charged into ia round bottom flask at 25°C. The reaction mass was stirred for 10 minutes at 5Q.°C. The reaction mass temperature cooled to 25°C. The reaction mass was filtered to remove any insoluble particles. The reaction mass was evaporated under vacuum" at 50°C for over 30 minutes.

We Claim
1. Crystalline form of fevipiprant selected from Forms A, B, C and D wherein,
a) crystalline Form A is characterized by XRD pattern having 29 value of 10.55, 12.10,17.51,21.16 and 24.38±O.2°0 and by Differential Scanning Calorimetry with peak at about 210.26°C;
b) crystalline Form B is characterized by XRD pattern having 20 value of 12.05, 13.60, 15.70 and 21.13±0.2°9 and by Differential Scanning Calorimetry with peak at about 212.61°C;
c) crystalline Form C is characterized by XRD pattern having 20 value of 4.97, 9.55, 13.79 and 21.69±O.2°0 and by Differential Scanning Calorimetry with peak atabout211.37°C;and
d) crystalline Form D is characterized by XRD pattern having 20 value of 10.52, 12.55, 19.56, and 28.31±0.2°0 and by Differential Scanning Calorimetry with peak at about 210.32°C.
2. A process for the preparation of crystalline form of fevipiprant comprising the
steps of:
a) adding fevipiprant in an organic solvent at 40-100°C to get a hot solution;
b) adding the hot solution to another solvent and cooling to 0-3 0°C; and
c) filtering and drying to get crystalline form of fevipiprant.

3. The process as claimed in claim 2, wherein said organic solvent used in step a) is selected from the group comprising of methyl isobutyl ketone, acetone, methyl tert-butyl ketone, ethanpl, methanol, n-propanol, butanol, isobutanol, tert-butanol, ethyl acetate, propyl acetate, n-pentyl acetate, isopropyl acetate, butyl acetate, 1,4-dibxane, tetrahydrofuran, methyl tetrahydrofuran and mixture thereof.
4. The process as.claimed in claim 2, wherein said solvent used in step b) is selected from n-heptane, cyclohexane, n-hexane, water, and mixture thereof.

5. A process for the preparation of crystalline Form A as claimed in claim 1,
wherein said process comprises the steps of:
a) adding fevipiprant in methyl isobutyl ketone at 65-90°C to get a hot solution;
b) adding the hot solution to ri-heptane and cooling to 20-30°C; and
c) filtering and drying to get crystalline Form A of fevipiprant.
6. A process for the preparation of crystalline Form B as claimed in claim 1, wherein
said process comprises the steps of:
a) adding fevipiprant in ethyl acetate at 50-60°C to get a hot solution;
b) adding the hot solution to n-heptane and cooling to 20-30°C; and
c) filtering and drying to get crystalline Form B of fevipiprant.
7. A process for the preparation of crystalline Form C as claimed in claim 1, wherein
said process comprises the steps of:
a) adding fevipiprant in methanol at 50-60°C to get a hot solution;
b) adding water to the hot solution and cooling to 20-30°C; and
c) filtering and drying to get crystalline Form C of fevipiprant.
8. A process for the preparation of crystalline Form D as claimed in claim 1,
wherein said process comprises the steps of:
a) adding fevipiprant in 1,4-dioxane at 55-65°C to get a hot solution;
b) adding the hot solution to n-heptane and cooling to 20-30°C; and
c) filtering and drying to get crystalline Form D of fevipiprant.
9. A process for the preparation of an amorphous solid dispersion of fevipiprant,
comprising the steps of:
a) providing a solution of fevipiprant in a suitable solvent;
b) adding atleast one pharmaceutically acceptable excipient to the solution obtained in step a); and
c) isolating the amorphous solid dispersion of fevipiprant.

10. The process as claimed in claim 9, wherein said pharmaceutical^ acceptable excipient are selected from the group comprising of silicon dioxide, titanium dioxide, zinc oxide, zinc dioxide, aluminium dioxide, zeolite, polyvinyl pyrrolidinone, cross linked cellulose acetate phthalate, microcrystalline cellulose, polyethylene/polyvinyl alcohol copolymer, polyethylene/polyvinyl pyrrolidinone copolymer, cross-linked carboxymethyl cellulose, povidone, povidone K-30, povidone K-60, Povidone K-90, polyvinyl pyrrolidone vinyl acetate, polyvinyl alcohol, polysorbate 80, polyethylene glycol, methyl cellulose, Eudragit S-100, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, gelucire 44/14, ethyl cellulose, D-alphatocopheryl polyethylene glycol 1000 succinate, cellulose acetate phthalate, carboxymethylethylcellulose, cellulose derivatives; polyethylene glycol, cyclodextrins, gelatins, hypromellose phthalates, sugars, polyhydric alcohols, mannitol, lactose, fructose, sorbitol, xylitol, maltodextrin, dextrates, dextrins, lactitol and mixture thereof.